Portal de Periódicos da CAPES

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer

2021; Cell Press; Volume: 40; Issue: 2 Linguagem: Inglês

10.1016/j.ccell.2021.12.013

1878-3686

Annika Fendler, Scott T.C. Shepherd, Lewis Au, Katalin A. Wilkinson, Mary Wu, Andreas M. Schmitt, Zayd Tippu, Sheima Farag, Aljosja Rogiers, Ruth Harvey, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Justine Korteweg, Tara Foley, Taja Barber, Andrea Emslie-Henry, Niamh Caulfield-Lynch, Fiona Byrne, Benjamin Shum, Camille L. Gérard, Daqi Deng, Svend Kjær, Ok‐Ryul Song, Christophe J. Queval, Caitlin Kavanagh, Emma Wall, Edward J Carr, Sina Namjou, Simon Caidan, Mike Gavrielides, James I. MacRae, Gavin Kelly, Kema Peat, Denise Kelly, Aida Murra, Kayleigh Kelly, Molly O’Flaherty, Robyn Shea, Gail Gardner, Darren R. Murray, Nadia Yousaf, Shaman Jhanji, Nicholas van As, Kate Young, Andrew Furness, Lisa Pickering, Rupert Beale, Charles Swanton, Sonia Gandhi, S.J. Gamblin, David L.V. Bauer, George Kassiotis, Michael Howell, Emma Nicholson, Susanna Walker, Robert J. Wilkinson, James Larkin, Samra Turajlic,

COVID-19 Clinical Research Studies

Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al., 2020), and they are currently prioritized globally for a third COVID-19 vaccine dose. Humoral and cellular immune responses are detected after two primary COVID-19 vaccine doses in most patients with cancer (Ehmsen et al., 2021; Fendler et al., 2021; Oosting et al., 2021), although neutralizing responses against variants of concern (VOCs) are reduced. Neutralizing responses are frequently impaired in patients with hematological malignancies, especially those receiving B cell-depleting therapies (Ehmsen et al., 2021; Fendler et al., 2021; Thakkar et al., 2021).